Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,424 USD | -2,46% | -58,35% | -42,03% |
Omzet 2023 * | - | Omzet 2024 * | - | Marktkapitalisatie | 1,63 mln. 1,51 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2023 * | -12 mln. -11,11 mln. | Nettowinst (verlies) 2024 * | - | EV/omzet 2023 * | - |
Nettoliquiditeiten 2023 * | - 0 | Nettoliquiditeiten 2024 * | - 0 | EV/omzet 2024 * | - |
K/w-verhouding 2023 * |
-0,06
x | K/w-verhouding 2024 * |
-
| Werknemers | 37 |
Dividendrendement 2023 * |
-
| Dividendrendement 2024 * |
-
| Vrij verhandelbaar | 86,56% |
Recentste transcriptie over NeuBase Therapeutics, Inc.
1 dag | -2,46% | ||
1 week | -58,35% | ||
Lopende maand | -50,12% | ||
1 maand | -50,98% | ||
3 maanden | -39,66% | ||
6 maanden | -54,36% | ||
Lopend jaar | -42,03% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Todd Branning
CEO | Chief Executive Officer | 54 | 10-01-22 |
Dani Stoltzfus
PRN | Corporate Officer/Principal | - | - |
Ron Sarkar
PRN | Corporate Officer/Principal | - | 01-11-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Dov Goldstein
CHM | Chairman | 56 | 12-07-19 |
Eric Richman
BRD | Director/Board Member | 63 | 12-07-19 |
Director/Board Member | 79 | 12-07-19 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
28-03-24 | 0,429 | -1,31% | 206 593 |
27-03-24 | 0,4347 | -9,21% | 656 232 |
26-03-24 | 0,4788 | -52,12% | 1 382 295 |
25-03-24 | 1 | -2,91% | 721 260 |
22-03-24 | 1,03 | 0,00% | 33 231 |
uitgestelde koers Nasdaq, 28 maart 2024 om 18:37 uur
Meer koersenVaira. 1 jan. | Kapi. | |
---|---|---|
-42,03% | 1,63 mln. | |
+9,23% | 45,97 mld. | |
+52,73% | 43,93 mld. | |
+7,79% | 42,34 mld. | |
-8,78% | 28,27 mld. | |
+18,60% | 27,18 mld. | |
-21,50% | 19,44 mld. | |
+14,76% | 13,83 mld. | |
+31,59% | 12,4 mld. | |
+7,15% | 11,45 mld. |